Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb

Slides:

Advertisements

Similar presentations

Faecalibacterium prausnitzii subspecies–level dysbiosis in the human gut microbiome underlying atopic dermatitis Han Song, PhD, Young Yoo, MD, PhD, Junghyun.

Advertisements

Panimmunoglobulin and IgE-selective extracorporeal immunoadsorption in patients with severe atopic dermatitis Kristian Reich, MD, PhD, Julia Deinzer,

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence Mariya Rozenblit, BA, Mayte Suarez-Farinas,

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study Eli O. Meltzer, MD, Paul.

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study

Alalia Berry, MD, William W. Busse, MD

Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: A meta- analysis of randomized clinical trials Yue Han, MD, Yuxin Chen,

Claus Bachert, PhD, Ana R. Sousa, PhD, Valerie J. Lund, MD, Glenis K

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

Vitamin D and antimicrobial peptide levels in patients with atopic dermatitis and atopic dermatitis complicated by eczema herpeticum: A pilot study Lujain.

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional.

Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis Jennifer D. Hamilton, PhD, Mayte Suárez-Fariñas,

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies Mark.

Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma Eric D. Bateman, MD, Udo-Michael.

Skin-homing and systemic T-cell subsets show higher activation in atopic dermatitis versus psoriasis Tali Czarnowicki, MD, Dana Malajian, BA, Avner Shemer,

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies Linda.

Serum periostin is associated with type 2 immunity in severe asthma

Reply Journal of Allergy and Clinical Immunology

Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis Howard Sofen, MD, Stacy.

Lawrence F. Eichenfield, MD, Lisa Beck, MD

Panimmunoglobulin and IgE-selective extracorporeal immunoadsorption in patients with severe atopic dermatitis Kristian Reich, MD, PhD, Julia Deinzer,

Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically useful? Ting Seng Tang, MBBS, Thomas.

Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study Kenji Kabashima, MD, PhD, Masutaka.

Anjali Shroff, MD, Emma Guttman-Yassky, MD, PhD JAAD Case Reports

Management of Difficult-to-Treat Atopic Dermatitis

High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects William Busse, MD, Sheldon Spector, MD, Karin Rosén,

Early decreases in blood eosinophil levels with reslizumab

What are the best outcome measurements for atopic eczema

Relationship between EASI and SCORAD severity assessments for atopic dermatitis Rishi Chopra, MS, Paras P. Vakharia, PharmD, Ryan Sacotte, BS, Neha Patel,

Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis Natalija Novak, MD,

Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma Oliver.

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis Jennifer D. Hamilton, PhD, Mayte Suárez-Fariñas,

Atopic Dermatitis: A Heterogeneous Disorder

News Beyond Our Pages Journal of Allergy and Clinical Immunology

What is an “eosinophilic phenotype” of asthma?

Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants Roland Kaufmann, MD, Regina Fölster-Holst, MD, Peter Höger, MD,

A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis Eric L. Simpson, Shinichi Imafuku, Yves Poulin, Benjamin Ungar, Lisa Zhou,

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by.

Jonathan I. Silverberg, MD, PhD, MPH, Joel M

Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial Sonja Ständer, MD, Paul Kwon, MD,

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: A randomized, double-blind, placebo-controlled study Giovanni B. Pajno,

New pathways for itching in patients with atopic dermatitis?

Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A

Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down Eric D. Bateman, MD, Loretta Jacques, PhD,

Journal of Allergy and Clinical Immunology

Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial Alice Gottlieb, MD, PhD, John Sullivan,

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Reply Journal of Allergy and Clinical Immunology

Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a.

A randomized trial of methotrexate versus azathioprine for severe atopic eczema Mandy Elvira Schram, MD, Evelien Roekevisch, MD, Mariska Maria Geertruida.

Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.

Interrupting IL-6–receptor signaling improves atopic dermatitis but associates with bacterial superinfection Alexander A. Navarini, MD, PhD, Lars E.

Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization.

Methotrexate versus azathioprine in patients with atopic dermatitis: 2-year follow-up data Evelien Roekevisch, MD, Mandy Elvira Schram, MD, PhD, Mariska.

The acquisition of tolerance toward cow's milk through probiotic supplementation: A randomized, controlled trial Jeroen Hol, MD, Eduard H.G. van Leer,

Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator’s.

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults Eric L. Simpson, MD, MCR,

Natural history of cow’s milk allergy

In lasting tribute: Burton Zweiman, June 7, 1931–December 24, 2013

Presentation transcript:

Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb Andreas Wollenberg, MD, Michael D. Howell, PhD, Emma Guttman-Yassky, MD, PhD, Jonathan I. Silverberg, MD, PhD, MPH, Christopher Kell, PhD, Koustubh Ranade, PhD, Rachel Moate, MSc, René van der Merwe, MBBS Journal of Allergy and Clinical Immunology DOI: 10.1016/j.jaci.2018.05.029 Copyright © 2018 The Authors Terms and Conditions

Fig 1 A-C, Adjusted mean change in EASI score from baseline over time for the ITT population (Fig 1, A∗), DPP-4-high subgroup (Fig 1, B†), and periostin-high subgroup (Fig 1, C‡). D-F, Adjusted percentage of participants with an IGA response at week 12 for the ITT population (Fig 1, D∗), DPP-4-high subgroup (Fig 1, E†), and periostin-high subgroup (Fig 1, F‡). Participants were considered IGA responders if they had an IGA response of 0 or 1 and a reduction of 2 grades or more from baseline to week 12. IGA severity categories are as follows: 0, clear; 1, almost clear; 2, mild; 3, moderate; 4, severe; and 5, very severe. ∗Participants randomized to treatment: placebo, n = 51; tralokinumab 45 mg, n = 50; tralokinumab 150 mg, n = 51; tralokinumab 300 mg, n = 52. †Participants randomized to treatment: placebo, n = 24; tralokinumab 45 mg, n = 25; tralokinumab 150 mg, n = 23; tralokinumab 300 mg, n = 30. ‡Participants randomized to treatment: placebo, n = 25; tralokinumab 45 mg, n = 24; tralokinumab 150 mg, n = 25; tralokinumab 300 mg, n = 28. Journal of Allergy and Clinical Immunology DOI: (10.1016/j.jaci.2018.05.029) Copyright © 2018 The Authors Terms and Conditions

Fig 2 Adjusted percentage of participants achieving a reduction of 50% or more (EASI50) and 75% or more (EASI75) in EASI score (A) and 50% or more in SCORAD score (SCORAD50; B) at week 12. Analyses were last observation carried forward, excluding data from participants who took prohibited medications. Journal of Allergy and Clinical Immunology DOI: (10.1016/j.jaci.2018.05.029) Copyright © 2018 The Authors Terms and Conditions

Fig 3 Adjusted mean change from baseline in SCORAD score (A), pruritus numeric rating scale (NRS) score (B), and Dermatology Life Quality Index (DLQI) score (C) for the ITT population. Journal of Allergy and Clinical Immunology DOI: (10.1016/j.jaci.2018.05.029) Copyright © 2018 The Authors Terms and Conditions

Fig E1 Journal of Allergy and Clinical Immunology DOI: (10.1016/j.jaci.2018.05.029) Copyright © 2018 The Authors Terms and Conditions

Fig E2 Journal of Allergy and Clinical Immunology DOI: (10.1016/j.jaci.2018.05.029) Copyright © 2018 The Authors Terms and Conditions